Clinical Trial Update: Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update for ublituximab addressing ocrelizumab wearing-off in people with multiple sclerosis; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ublituximab (ublituximab)

Snippet

Sponsor: Johns Hopkins University | Conditions: Multiple Sclerosis | Phase 4 | Status: NOT_YET_RECRUITING